SECURITIES ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important January 12, 2015 Deadline in Class Act...
December 28 2014 - 12:01AM
Rosen Law Firm reminds purchasers of Aeterna Zentaris, Inc.
securities (Nasdaq:AEZS) between October 18, 2012 and November 6,
2014 of the important January 12, 2015 lead plaintiff deadline in
the class action filed by the firm.
To join the AEZS class action, go to the website at
http://rosenlegal.com/cases-429.html or call Phillip Kim, Esq. or
Jonathan Horne, Esq. toll-free at 866-767-3653 or email
pkim@rosenlegal.com or jhorne@rosenlegal.com for information on the
class action. The suit is pending in U.S. District Court for
the District of New Jersey.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL
A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR
CHOICE.
According to the lawsuit, the Company misstated information
about its New Drug Application ("NDA") with the FDA. On
October 18, 2012, the Company announced the Phase III clinical
trial results of its drug MACRILEN™ ("MACRILEN"), stating that the
results "confirm [MACRILEN's] potential as possibly the first
approved oral diagnostic test for [adult growth hormone
deficiency]." The Phase III trials were conducted pursuant to a
Special Protocol Assessment that was agreed upon with the FDA. The
Company then filed an NDA for MACRILEN.
On November 6, 2014, the Company announced that the FDA would
not approve the Company's MACRILEN NDA, as it had received a
Complete Response Letter ("CRL"). The Company stated that the FDA's
concerns were:
"[T]hat the planned analysis of the Company's pivotal trial did
not meet its stated primary efficacy objective as agreed to
in the Special Protocol Assessment agreement letter between the
Company and the FDA. The CRL further mentioned issues
related to the lack of complete and verifiable source data for
determining whether patients were accurately diagnosed with AGHD.
The FDA concluded that, "in light of the failed primary
analysis and data deficiencies noted, the clinical trial does not
by itself support the indication." To address the
deficiencies identified above, the CRL states that the Company will
need to demonstrate the efficacy of macimorelin as a diagnostic
test for growth hormone deficiency in a new, confirmatory clinical
study." That day, the Company's stock price fell from
$1.29 to $0.65, damaging investors.
If you wish to join the litigation and recover your losses go to
http://rosenlegal.com/cases-429.html or to discuss your rights or
interests regarding this class action, please contact, Phillip Kim,
Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail
at pkim@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
CONTACT: Laurence Rosen, Esq.
Phillip Kim, Esq.
Jonathan Horne, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
jhorne@rosenlegal.com
www.rosenlegal.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024